Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes

被引:28
|
作者
Engelen, Suzanne E. [1 ]
van der Graaf, Yolanda [5 ]
Stam-Slob, Manon C. [1 ]
Grobbee, Diederick E. [5 ]
Cramer, Maarten J. [2 ]
Kappelle, L. Jaap [3 ]
de Borst, Gert J. [4 ]
Visseren, Frank L. J. [1 ]
Westerink, Jan [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
关键词
Type; 2; diabetes; Cardiovascular disease; Interventions; PERIPHERAL ARTERIAL-DISEASE; SIROLIMUS-ELUTING STENTS; OUTCOMES; THROMBOSIS; MELLITUS; RISK; MORTALITY;
D O I
10.1016/j.ijcard.2017.07.081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diabetes mellitus is associated with an increased risk for cardiovascular morbidity and mortality. The vascular burden in terms of incidence of cardiovascular events (CVE) and vascular interventions is however poorly quantified. In this study we evaluated the incidence rates of CVE and vascular interventions in patients with type 2 diabetes (T2DM) with and without cardiovascular disease (CVD) in comparison to patients without type 2 diabetes. Research design and methods: In a cohort of 9.808 high-risk patients with and without cardiovascular disease and type 2 diabetes originated from the ongoing, single-center prospective SMART (Second Manifestations of ARTerial disease) cohort, the number and incidence rates of CVE and interventions were calculated. The incidence rates were adjusted for confounders using Poisson regression models. CVE were defined as vascular death, stroke and myocardial infarction (MI). Interventions were defined as percutaneous coronary intervention, coronary artery bypass grafting, percutaneous transluminal angioplasty or stenting of the peripheral arteries and amputation. Results: Patients with T2DM and CVD had a 4-fold higher incidence rate of CVE and a 8-fold higher incidence rate of vascular interventions compared to high-risk patients without T2DM and CVD after adjusting for confounders. The incidence rate for the composite of non-fatal MI, non-fatal stroke and vascular death was 5.8 per 1000 person-years in patients without T2DM or CVD at baseline, 15.2 per 1000 person-years in patients with T2DM but without CVD at baseline, 26.0 per 1000 person-years in patients without T2DM but with CVD and 40.7 per 1000 person-years in patients with both T2DM and CVD at baseline. A similar increasing incidence rate was seen for all vascular interventions from patients without T2DM or CVD to patients with both T2DM and CVD. Conclusions: Patients with type 2 diabetes or CVD are subject to an increased incidence of cardiovascular events and interventions compared to high-risk patients without type 2 diabetes or vascular disease. Patients with type 2 diabetes and CVD have the highest incidence of new cardiovascular diseases and vascular interventions when compared to patients without type 2 diabetes and CVD. These results underline the need for optimal risk factor treatment as well as the need for new prevention and treatment strategies in this very high risk population. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [1] Influence of the location and the extent of vascular disease on new cardiovascular events in patients with type 2 diabetes
    Gorter, P. M.
    Visseren, F. L. J.
    Algra, A.
    van der Graaf, Y.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2006, 21 : 20 - 20
  • [2] Atorvastatin reduces cardiovascular events in patients with type 2 diabetes
    不详
    DIABETES OBESITY & METABOLISM, 2003, 5 (06): : 472 - 472
  • [3] Influence of the location and the extent of atherosclerotic vascular disease on new cardiovascular events in patients with type 2 diabetes
    Gorter, P. M.
    Visseren, F. L. J.
    Algra, A.
    van der Graaf, Y.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 335 - 335
  • [4] Association between Nutritional Recommendations for Cardiovascular Disease and a Lower Incidence of Cardiac Events in Patients with Type 2 Diabetes
    dos Santos, Ana Luiza Teixeira
    Weiss, Tanara
    Duarte, Camila Kummel
    Cantori, Gabriela Azambuja
    de Azevedo, Mirela Jobim
    Gross, Jorge Luiz
    Zelmanovitz, Themis
    DIABETES, 2010, 59 : A51 - A51
  • [5] Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015
    Jodar, Esteban
    Artola, Sara
    Garcia-Moll, Xavier
    Uria, Estefany
    Lopez-Martinez, Noemi
    Palomino, Rosa
    Martin, Virginia
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [6] Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis
    Zhang, Chun-Yu
    Sun, Ai-Jun
    Zhang, Shu-Ning
    Wu, Chao-Neng
    Fu, Ming-Qiang
    Xia, Guang
    Wang, Ke-Qiang
    Zou, Yun-Zeng
    Ge, Jun-Bo
    ANNALS OF MEDICINE, 2010, 42 (04) : 305 - 315
  • [7] Disparities in the control of Diabetes type 2 and incidence of cardiovascular events. The APNA study
    Guillen Grima, F.
    Guillen Aguinaga, S.
    Brugos Larumbe, A.
    Forga Llenas, L.
    Guillen Aguinaga, L.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31 : 416 - 416
  • [8] Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations
    Stam-Slob, Manon C.
    van der Graaf, Yolanda
    de Borst, Gert Jan
    Cramer, Maarten J.
    Kappelle, L. J.
    Westerink, Jan
    Visseren, Frank L.
    DIABETES CARE, 2015, 38 (08) : 1528 - 1535
  • [9] Circulating sclerostin as a predictor of cardiovascular events in Type 2 diabetes patients
    Munoz-Torres, Manuel
    Novo-Rodriguez, Cristina
    Reyes-Garcia, Rebeca
    Rozas-Moreno, Pedro
    Garcia-Martin, Antonia
    Avila-Rubio, Veronica
    Morales-Santana, Sonia
    Garcia-Fontana, Beatriz
    Escobar-Jimenez, Fernando
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S290 - S290
  • [10] Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes
    Krzyzanowska, Katarzyna
    Mittermayer, Friedrich
    Wolzt, Michael
    Schernthaner, Guntram
    DIABETES CARE, 2007, 30 (07) : 1834 - 1839